When someone is diagnosed with multiple myeloma, one of the first questions is often painfully simple: “Why did this happen?” Unfortunately, this blood cancer does not arrive with a tidy receipt listing the cause. Researchers understand many of the biological changes that drive the disease, but they usually cannot identify one event, exposure, habit, or inherited gene that explains an individual case.
Multiple myeloma develops when plasma cells in the bone marrow acquire genetic abnormalities that allow them to multiply excessively, crowd out healthy blood-forming cells, and produce abnormal proteins. These changes usually accumulate over time rather than being inherited at birth. Age, precursor plasma-cell disorders, family history, excess body weight, sex, ancestry, and certain environmental exposures can influence risk, but none acts as a guaranteed trigger. Biology, as usual, prefers a complicated group project over a single obvious villain.
What Causes Multiple Myeloma?
The exact cause of multiple myeloma remains unknown. Doctors know that the disease begins with abnormal plasma cells, which are immune-system cells responsible for making antibodies. A normal plasma cell helps defend the body from infection. A myeloma cell, by contrast, copies itself repeatedly, produces excessive amounts of one abnormal antibody or antibody fragment, and gradually disrupts the bone marrow environment.
In most cases, multiple myeloma appears to develop through several stages. A plasma cell first acquires an initiating genetic abnormality. Additional DNA changes then accumulate, helping abnormal cells survive, avoid normal growth controls, influence surrounding bone marrow cells, and eventually cause organ damage. There is rarely one dramatic “myeloma mutation.” Instead, the disease resembles a stack of small biological errors that becomes increasingly unstable over time.
The Genetic Changes Behind Multiple Myeloma
Somatic mutations are usually more important than inherited mutations
The word genetic can be confusing because it does not always mean hereditary. Most genetic abnormalities found in multiple myeloma are somatic changes. That means they develop in plasma cells during a person’s lifetime and are not present in every cell of the body. They are not normally passed from a parent to a child.
Common early abnormalities include chromosome translocations, in which pieces of chromosomes exchange places, and hyperdiploidy, in which a cell contains extra copies of certain chromosomes. Many translocations involve chromosome 14, where genes responsible for antibody production are located. When growth-regulating genes are moved near these highly active antibody genes, the result can be an unwanted growth signal with its foot stuck on the accelerator.
As abnormal plasma cells evolve, they may acquire additional changes involving pathways that control cell division, DNA repair, inflammation, and programmed cell death. Changes affecting genes such as KRAS, NRAS, BRAF, TP53, MYC, FGFR3, and DIS3 have been found in subsets of patients. No single mutation appears in everyone, which is one reason multiple myeloma behaves differently from person to person.
Inherited susceptibility can still play a role
Multiple myeloma is generally not classified as a straightforward hereditary cancer. There is no single commonly inherited “myeloma gene” comparable to the best-known hereditary mutations associated with some breast or colorectal cancers. Nevertheless, close relatives of someone with multiple myeloma or another plasma-cell disorder have a higher risk than people without that family history. Researchers have identified inherited genetic variants that may modestly increase or decrease susceptibility.
Family clustering remains uncommon. Most people diagnosed with multiple myeloma do not have a parent, sibling, or child with the disease. Even when a first-degree relative is affected, the higher relative risk does not mean multiple myeloma is inevitable. Because the cancer is uncommon in the general population, a several-fold increase can still translate into a relatively small absolute lifetime risk.
MGUS and Smoldering Myeloma: The Precursor Stages
Research indicates that active multiple myeloma is usually preceded by a plasma-cell condition called monoclonal gammopathy of undetermined significance, or MGUS. People with MGUS have a small population of abnormal plasma cells and an abnormal protein in the blood, but they do not have the organ damage that defines active myeloma. MGUS is often discovered accidentally during routine blood testingthe medical equivalent of finding an unexpected browser tab you do not remember opening.
Most people with MGUS never develop multiple myeloma. On average, approximately 1% of people with MGUS progress to myeloma or a related disorder each year, although individual risk varies according to the type and amount of abnormal protein, free light-chain measurements, and other laboratory findings. Regular monitoring helps doctors detect meaningful changes without treating a condition that may remain stable for decades.
Smoldering multiple myeloma sits between MGUS and active disease. It involves a larger burden of abnormal plasma cells or abnormal protein but does not yet cause classic myeloma-related organ damage. Its progression risk is higher than that of MGUS, particularly during the first several years after diagnosis. Smoldering myeloma is not simply “early-stage active myeloma”; it is a distinct condition requiring individualized risk assessment and careful surveillance.
Established and Suspected Multiple Myeloma Risk Factors
Older age
Age is one of the strongest risk factors. Most people are diagnosed after age 65, and the median age at diagnosis is approximately 69. Multiple myeloma can occur in younger adults, but fewer than 1% of cases are diagnosed before age 35. Aging gives cells more time to accumulate DNA damage, and age-related changes in immunity and the bone marrow environment may help abnormal plasma cells survive.
Male sex
Men develop multiple myeloma slightly more often than women. Researchers have not identified one definitive explanation. Hormonal influences, immune-system differences, occupational exposures, body composition, and genetic factors have all been considered, but the sex difference is modest and does not predict who will personally develop the disease.
Black race and African ancestry
In the United States, multiple myeloma occurs more than twice as often among Black people as among White people, and Black patients are often diagnosed at a younger age. Black Americans also have a higher prevalence of MGUS, the precursor condition. The reasons remain under investigation and probably involve a combination of ancestry-related genetic susceptibility, differences in precursor biology, environmental influences, social conditions, and patterns of medical access.
Race itself is not a single biological mechanism, and higher incidence should not be confused with worse treatment response. Evidence suggests that when patients receive timely access to specialists and modern therapies, outcomes can be comparable across racial groups. Unequal access, delayed diagnosis, insurance barriers, transportation challenges, and underrepresentation in clinical trials can influence real-world outcomes independently of tumor biology.
Family history
Having a parent, sibling, or child with multiple myeloma increases risk, although familial cases account for only a small fraction of diagnoses. A family history of MGUS or certain related blood cancers may also indicate increased susceptibility. Families with several affected relatives, unusually young diagnoses, or multiple types of blood cancer may benefit from a conversation with a hematologist or genetic counselor.
Excess body weight and obesity
Excess body weight is a recognized modifiable risk factor for multiple myeloma. Researchers are studying several possible mechanisms, including chronic low-grade inflammation, altered insulin signaling, changes in adipokines produced by fat tissue, and effects on the bone marrow microenvironment. Obesity does not directly “cause” every case, but maintaining a healthy weight may help reduce risk while also benefiting cardiovascular, metabolic, and joint health.
Radiation and chemical exposures
High-dose ionizing radiation and exposure to certain chemicals have been associated with a higher risk of multiple myeloma. Substances studied include benzene, some industrial pesticides, herbicides such as Agent Orange, petroleum-related products, fertilizers, and other occupational chemicals. Agricultural, petrochemical, metalworking, firefighting, and military exposures have received particular research attention.
These associations require careful interpretation. Many studies rely on occupational history or estimated past exposure, making it difficult to identify the responsible substance, dose, or duration. A person may have worked around chemicals and never develop myeloma, while another person with no recognized exposure may be diagnosed. In an individual case, exposure history usually cannot prove exactly what caused the cancer.
Other plasma-cell disorders
MGUS, smoldering multiple myeloma, and solitary plasmacytoma are among the most important medical risk factors. These conditions already involve an abnormal clone of plasma cells, giving those cells an opportunity to acquire additional changes. A diagnosis of one of these disorders does not mean progression is certain, but it makes scheduled monitoring essential.
What Has Not Been Proven to Cause Multiple Myeloma?
No specific food, routine household product, emotional state, minor injury, or everyday infection has been established as a direct cause of multiple myeloma. Smoking and alcohol are major risk factors for several cancers, but neither is considered a clearly established leading cause of myeloma. Likewise, stress may affect sleep, blood pressure, and quality of life, but there is no evidence that a stressful job or difficult year independently creates myeloma cells.
It is also important not to mistake symptoms for causes. Back pain, fatigue, anemia, repeated infections, kidney problems, fractures, and high blood calcium can result from multiple myeloma; they do not normally create the disease. A sore back did not “turn into cancer,” even when back pain was the symptom that finally led to testing.
Can Multiple Myeloma Be Prevented?
There is currently no guaranteed way to prevent multiple myeloma. Most major risk factors, including age, sex, ancestry, family history, and spontaneous DNA changes, cannot be modified. Avoiding unnecessary radiation, following workplace safety procedures, using protective equipment around industrial chemicals, and maintaining a healthy body weight are reasonable health measures, but they cannot eliminate risk.
People diagnosed with MGUS or smoldering myeloma should attend recommended follow-up visits. Monitoring may include blood counts, kidney-function tests, calcium measurements, serum protein studies, free light-chain tests, urine tests, imaging, or bone marrow evaluation. The goal is not to spend every morning interrogating your skeleton. It is to identify meaningful progression early while avoiding unnecessary treatment.
Should Family Members Get Genetic Testing or Screening?
Routine genetic testing or population-wide screening for multiple myeloma is not currently recommended for everyone. Testing the myeloma cells obtained from a bone marrow sample is common after diagnosis, but this is usually tumor testing rather than inherited-risk testing. Techniques such as fluorescence in situ hybridization, or FISH, identify chromosome abnormalities that can help estimate prognosis and guide treatment decisions. They do not necessarily reveal changes that relatives might inherit.
Germline testing examines DNA inherited from a person’s parents, often using blood or saliva. A hematologist or genetic counselor may consider it when several relatives have plasma-cell disorders, blood cancers occur across generations, or someone develops myeloma at an unusually young age. Research screening programs are also studying people with African ancestry and first-degree relatives of patients, but research participation is different from universal clinical screening.
Experiences That Often Shape the Risk-Factor Conversation
The following examples are fictional composites based on common questions raised by patients and families. They are not descriptions of specific individuals.
Experience 1: “My mother had myeloma. Am I next?”
Imagine a 48-year-old woman whose mother was recently diagnosed with multiple myeloma. She searches online, sees the words “genetic mutations,” and assumes that a microscopic countdown has started inside her own bone marrow. Her first useful discovery is that genetic does not automatically mean inherited. Her mother’s myeloma cells may contain numerous mutations, but most probably developed only in those cells during her mother’s lifetime.
The daughter’s family history may raise her risk somewhat, but it does not make a diagnosis likely or inevitable. A productive medical visit focuses on the full family history: Which relatives had blood cancers? At what ages? Were any diagnosed with MGUS, lymphoma, leukemia, or amyloidosis? One affected older relative is different from several closely related people diagnosed unusually young. Instead of ordering a random collection of direct-to-consumer tests, she can ask whether consultation with a hematologist or genetic counselor is appropriate.
Experience 2: Living with MGUS without letting it move into the guest room
A 67-year-old man learns that he has MGUS after blood work performed for an unrelated problem. He feels healthy, yet the phrase “can progress to multiple myeloma” follows him around like an unwanted notification. At first, every ache feels suspicious. A sore shoulder after gardening becomes “bone pain.” Afternoon sleepiness becomes “severe fatigue.” The internet, always eager to help, offers twelve rare diseases before breakfast.
His hematologist explains that MGUS is common among older adults and that most cases never progress. The practical experience of MGUS is therefore less about treatment and more about learning to tolerate structured uncertainty. He keeps follow-up appointments, tracks laboratory trends rather than obsessing over one isolated number, and reports persistent or unexplained symptoms. Monitoring becomes a routine safety systemnot a prediction that cancer is waiting around the corner.
Experience 3: Looking back at workplace exposure
A retired agricultural worker diagnosed with myeloma may wonder whether decades around pesticides caused the disease. That question deserves respect, especially because occupational studies have found associations involving pesticides, fuels, solvents, and related exposures. However, an association cannot usually determine the cause of one person’s cancer. Exposure may have contributed, or it may not have been biologically important in that individual case.
The useful next steps include documenting employers, job duties, chemical names, exposure periods, protective equipment, military service, and any known high-dose incidents. This information may help the medical team, occupational-health specialists, benefit programs, or research registries. What is generally not useful is self-blame. Workers often used products considered acceptable at the time, sometimes with incomplete safety information. Cancer biology is complicated enough without adding a courtroom inside your own head.
Experience 4: Asking better questions after diagnosis
After a new diagnosis, patients sometimes ask, “What did I do wrong?” A more helpful set of questions is: Do I have a history of MGUS or smoldering myeloma? What chromosome or gene abnormalities were found in my bone marrow? Are those changes acquired or possibly inherited? Does my family history suggest genetic counseling? Are my relatives eligible for a clinical screening study? What symptoms should prompt an urgent call?
These questions turn an unanswerable search for blame into a plan for understanding the disease. The cause of multiple myeloma is rarely one inherited variant, one chemical exposure, or one lifestyle decision. It is usually the outcome of acquired genetic changes interacting with age, the immune system, the bone marrow environment, inherited susceptibility, and other risk factors that science is still working to untangle.
Conclusion
Multiple myeloma is fundamentally a genetic disease of plasma cells, but it is usually not a directly inherited disease. Most cancer-driving mutations arise during life and accumulate through precursor stages such as MGUS and smoldering myeloma. Older age, male sex, Black race or African ancestry, family history, excess body weight, certain plasma-cell disorders, radiation, and selected occupational exposures are associated with increased risk.
Risk factors are clues, not verdicts. Many people with several risk factors never develop myeloma, and many patients are diagnosed without any obvious exposure or family history. Understanding the difference between acquired tumor mutations, inherited susceptibility, and population-level associations can help patients and families replace blame with informed medical follow-up.
Note: This article is intended for general education and does not replace evaluation by a hematologist, oncologist, genetic counselor, or other qualified healthcare professional. People with persistent bone pain, unexplained anemia, recurring infections, kidney abnormalities, high calcium, abnormal protein tests, MGUS, or a significant family history should discuss appropriate evaluation with their medical team.
